The recent expansion of Novo Nordisk A/S’s NVO Wegovy’s (semaglutide) FDA approval has sparked a debate over insurance coverage for the drug.  However,…

Read more

As the weight-loss frenzy fueled by social media endorsements and Hollywood glamour continues to surge, the battle against counterfeit medications has…

Read more

In response to growing reports of patient harm caused by counterfeit versions of its popular diabetes drug, Ozempic (semaglutide), Novo Nordisk…

Read more

Novo Nordisk A/S NVO’s Wegovy garnered the Food and Drug Administration’s approval for expanded use Friday, marking what the drugmaker…

Read more

Novo Nordisk A/S’s NVO head of development, Martin Holst Lange, expressed strong confidence in the drugmaker’s ability to launch the pill version…

Read more

A new study found that the interaction between cannabis and popular weight-loss drugs such as Ozempic and Wegovy can have…

Read more

Thursday, Novo Nordisk A/S NVO is holding its Capital Markets Day. Its executive management and other members of senior management will provide…

Read more

Editor’s note: This story has been updated to reflect a new press release issued by Novo Nordisk that clarifies details…

Read more